Aethlon Medical, a San Diego, CA firm, just announced that the FDA has given approval to a protocol for clinicians treating Ebola patients with the company’s Hemopurifier device. Already successfully used in Germany to save a critically ill patient, the Hemopurifier filters out viruses and shed glycoproteins from blood in daily sessions lasting up to eight hours. In the German case, the physician treating the patient reported that the device captured 242 million individual Ebola viruses, with further analysis confirming the findings.

The FDA is allowing up to 20 potential patients to be treated in the study with the Hemopurifier, with up to 10 hospitals cleared to participate. The company is currently studying the device for treating Hepatitis C with patients on chronic dialysis, and the Ebola study is based on its protocol

source:Aethlon Medical